All four country expansions announced last year were in place at the start of Q1, and as result of a well-established approach to training and new hire support, we saw initial contributions in line with expected productivity.

May 5, 2026 / receipt

You know, all the longer-term sort of secular tailwinds we believe are intact. It obviously starts today. with the overall humanization of pets, and that continues to strengthen. You know, appreciably and increasingly among the younger household-owning pets, from a demographic standpoint, what they've shown, both in terms of intent and actual actions, is willing to spend more and prioritize vis-a-vis categories like travel, entertainment, going out.

Aug 6, 2024 / receipt, needs a key / Jay, CFO | earnings call 2024-08-06 | transcript 875dae9c-4b7e-4051-9174-f0714fc73bca | chars 29869-30322 | segment 30

As we highlighted coming into the year, we knew that we had some costs coming back here, just more interface with our customers, more travel. I think we're anticipating that to continue.

May 2, 2023 / receipt, needs a key / Brian, CFO | earnings call 2023-05-02 | transcript 206b3c44-b0e1-4e21-aefe-48845c4c2080 | chars 28227-28413 | segment 28

We also expect to see relative increases in costs such as employee health care claims and travel as pandemic-related restrictions are eased.

Jul 30, 2021 / receipt, needs a key / Brian McKeon, CFO | earnings call 2021-07-30 | transcript 21bad2b9-b98b-412a-9df6-2825d5a582ba | chars 13750-13890 | segment 14

It seems like you're expecting some incremental spend, some T&E coming back, some healthcare costs going higher. Could you walk us through the cadence of that and how we expect that to come back?

Jul 30, 2021 / receipt, needs a key / Michael, other | earnings call 2021-07-30 | transcript 21bad2b9-b98b-412a-9df6-2825d5a582ba | chars 32135-32330 | segment 32

And as the pandemic progresses, conditions hopefully continue to get eased. We expect to see some T&E come back.

Jul 30, 2021 / receipt, needs a key / Brian McKean, CFO | earnings call 2021-07-30 | transcript 21bad2b9-b98b-412a-9df6-2825d5a582ba | chars 32994-33106 | segment 33

And so it gets a little noisy. As we work through the year, we started reinstating aspects of that, but we basically kept headcount controls in place and benefited from pretty significant year-on-year reductions in things like T&E and healthcare costs.

Jul 30, 2021 / receipt, needs a key / Brian, other | earnings call 2021-07-30 | transcript 21bad2b9-b98b-412a-9df6-2825d5a582ba | chars 47053-47305 | segment 48

Our 2020 financial outlook includes expectations for an increased rate of OPEX growth moving forward as we lap comparisons to control prior OPEX levels and invest to support our strong global growth momentum through enhancements to our commercial and innovation capability. We're also planning for year-on-year increases in costs in key areas, such as employee healthcare claims and travel costs, as we work through the year and pandemic-related restrictions are eased.

May 12, 2021 / receipt, needs a key / Brian McKeon, CFO | earnings call 2021-05-12 | transcript 4f5a216d-fd20-454c-9402-81b12124dd2d | chars 12876-13345 | segment 13

We also expect some relative year-on-year increases in costs in certain areas, such as employee health care costs, claims, and travel costs, as pandemic-related restrictions are eased.

Feb 2, 2021 / receipt, needs a key / Brian, CFO | earnings call 2021-02-02 | transcript b17e5a71-d220-4120-a6f6-70fa767c53df | chars 16873-17057 | segment 17

The majority of IDEX employees continue to work remotely, and travel remains highly restricted.

Jul 31, 2020 / receipt, needs a key / Jay (CEO), CEO | earnings call 2020-07-31 | transcript 22080efe-7820-431e-9128-fd46cf033bab | chars 27677-27772 | segment 28

Performance during the first quarter builds confidence to increase our full year revenue range, to between $4,675MM - $4,760MM, an increase of $42MM at mid-point, or an outlook for overall reported re

ir_statement / Aug 25, 2026 / receipt

We are also updating our full year EPS outlook to $14.45 - $14.90 per share - an increase of $0.13 per share at midpoint, net of a $0.05 negative impact from a loss on an equity investment in Q1 - ref

ir_statement / Aug 25, 2026 / receipt

At mid-point we are updating our estimate for US clinical visit to a decline of -1.5%, after a third sequential quarter of clinical visits trending between -1% to -2% and aligned with a trailing twelv

ir_statement / Aug 25, 2026 / receipt

Comparable operating expenses increased 11% year-over-year, as we advance investments in our global commercial and innovation capabilities.

ir_statement / Aug 25, 2026 / receipt

Turning to our full year 2026 - as noted, we're increasing our outlook for overall revenue to $4,675MM - $4,760MM.

ir_statement / Aug 25, 2026 / receipt

For the second quarter, we are planning for reported revenue growth of 7.3% - 9.3%

ir_statement / Aug 25, 2026 / receipt

Our EPS outlook incorporates increased projections for operational performance of $0.13 per share at mid-point compared to our prior guide

ir_statement / Aug 25, 2026 / receipt

Our updated full year EPS outlook is $14.45 to $14.90 per share, an increase of $0.13 per share at midpoint.

ir_statement / Aug 25, 2026 / receipt

Second quarter reported operating margins are expected to be 33.9% - 34.3%, reflecting expansion of 10 - 50 basis points on a comparable basis

ir_statement / Aug 25, 2026 / receipt

we are updating our reported operating margin outlook to 32.1% - 32.5% for 2026

ir_statement / Aug 25, 2026 / receipt

All four country expansions announced last year were in place at the start of Q1, and as result of a well-established approach to training and new hire support, we saw initial contributions in line wi

ir_statement / Aug 25, 2026 / receipt

We work alongside veterinarians and practice teams to better integrate diagnostics into everyday care protocols-supporting workflow optimization, increasing clinical confidence, and demonstrating the

ir_statement / Aug 25, 2026 / receipt